Overview

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
Phase:
Phase 2
Details
Lead Sponsor:
Concert Pharmaceuticals